Loss narrows year-over-year. Apyx Medical Corporation (NASDAQ: APYX) reported an adjusted loss of $0.06 per share for Q4 2025, narrowing 50% from the $0.12 per share loss in Q4 2024. The medical device maker’s GAAP loss came in at $0.03 per share, with the net loss totaling $1.3 million. No consensus estimate was available for comparison.
Revenue surges 34.8%. Q4 2025 revenue reached $19.2 million, up 34.8% from $14.2 million in the year-ago quarter. The company generated gross profit of $12.0 million against cost of revenue of $7.2 million, while adjusted EBITDA turned positive at $700,000. Management issued fiscal 2026 revenue guidance of $57.5 million to $58.5 million. Shares traded at $3.12 on volume of 188,565, with the stock flat on the day.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.